Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study
CANCER RESEARCH（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined